Anti-neoplastic biosimilars-the same rules as for cytotoxic generics cannot be applied

Annals of Oncology

Volumn 24, Issue SUPPLEMENT5, 2013, Pages

  Mellstedt, H ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

Author keywords

Biosimilar; Monoclonal antibodies; Oncology

Indexed keywords

BEVACIZUMAB; BIOSIMILAR AGENT; CETUXIMAB; CYTOTOXIC AGENT; GENERIC DRUG; MONOCLONAL ANTIBODY; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; RECOMBINANT ERYTHROPOIETIN; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; RITUXIMAB; TRASTUZUMAB; ANTINEOPLASTIC AGENT;

ARTICLE; B CELL LYMPHOMA; BREAST CANCER; DRUG APPROVAL; DRUG COST; DRUG EFFICACY; DRUG MANUFACTURE; DRUG SAFETY; HEALTH CARE COST; HEALTH CARE SYSTEM; HUMAN; IMMUNOGENICITY; MALIGNANT NEOPLASTIC DISEASE; MEDICAL SOCIETY; NEUTROPENIA; PATENT; PRACTICE GUIDELINE; PRIORITY JOURNAL; RISK BENEFIT ANALYSIS; TREATMENT INDICATION; ECONOMICS; EUROPE; LEGISLATION AND JURISPRUDENCE; NEOPLASMS;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; BIOSIMILAR PHARMACEUTICALS; DRUG APPROVAL; EUROPE; HUMANS; NEOPLASMS;

EID: 84882957437     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdt325     Document Type: Article

References (18)

1. European Medicines Agency. Committee for Medicinal Products for Human Use. Biosimilar Guidelines. http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/general/general_content_000408.jsp
2. European Commission. Directive 2001/83/EC Art. 10(4) and Part II of the Annexz I of Directive 2001/83/EC, as amended. EudraLex, Volume 1, Pharmaceutical legislation medicinal products for human use (accessed 20 July 2011). http://ec. europa.eu/health/files/eudralex/vol-1/dir_2001_83_cons2009/2001_83_cons2009_en.pdf
3. Weise M, Bielsky MC, De Smet K et al. Biosimilars-why terminology matters. Nat Biotechnol 2011; 29: 690-693.
4. Minghetti P, Rocco P, Cilurzo F et al. The regulatory framework of biosimilars in the European Union. Drug Discov Today 2012; 17: 63-70.
5. Niederwieser D, Schmitz S. Biosimilar agents in oncology/haematology: from approval to practice. Eur J Haematol 2011; 86: 277-288.
6. Braido F, Holgate S, Canonica GW. From 'blockbusters' to 'biosimilars': An opportunity for patients, medical specialists and health care providers. Pulm Pharmacol Ther 2012; 25: 483-486.
7. Roger SD. Biosimilars: current status and future directions. Expert Opin Biol Ther 2010; 10: 1011-1018.
8. European Medicines Agency. Guideline on Similar Biological Medicinal Products Containing Monoclonal Antibodies - non-Clincical and Clinical Issues. http://www. ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2012/06/WC500128686.pdf. 2012.
9. Coiffier B, Thieblemont C, Van Den Neste E et al. Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe d'Etudes des Lymphomes de l'Adulte. Blood 2010; 116: 2040-2045.
10. Recher C, Coiffier B, Haioun C et al. Intensified chemotherapy with ACVBP plus rituximab versus standard CHOP plus rituximab for the treatment of diffuse large B-cell lymphoma (LNH03-2B): an open-label randomised phase 3 trial. Lancet 2011; 378: 1858-1867.
11. Cabanillas F. Curability of advanced indolent or low-grade follicular lymphomas: time for a new paradigm? J Clin Oncol 2013; 31: 14-16.
12. Roy PS, Sengar M, Menon H et al. A retrospective single centre analysis of safety, toxicity and efficacy of rituximab (original) and its biosimilar in diffuse large B-cell lymphoma patients treated with chemo-immunotherapy. ECCO 2012. Abstr 1074. Ann Oncol 2012; 23: ix351.
13. Hale G, Rebello P, Brettman LR et al. Blood concentrations of alemtuzumab and antiglobulin responses in patients with chronic lymphocytic leukemia following intravenous or subcutaneous routes of administration. Blood 2004; 104: 948-955.
14. van den Bemt BJ, den Broeder AA, Wolbink GJ et al. Anti-infliximab antibodies are already detectable in most patients with rheumatoid arthritis halfway through an infusion cycle: an open-label pharmacokinetic cohort study. BMC Musculoskelet Disord 2011; 12: 12.
15. Läkemedelsverket. Utredning av förutsättningar för utvidgat utbyte respektive utbyte vid nyinsättning. Läkemedelsverket (Medical Products Agency) 2011-09-26. http://www.lakemedelsverket.se/upload/nyheter/2011/Regeringsuppdrag% 20utbytbarhet%20rapport%20sept%202011.pdf
16. Ebbers HC, Muenzberg M, Schellekens H. The safety of switching between therapeutic proteins. Expert Opin Biol Ther 2012; 12: 1473-1485.
17. Blackstone EA, Fuhr JP. Innovation and Competition: Will Biosimilars Succeed?. Biotechnology Healthcare 2012; 9: 24-27.
18. Up-take of filgrastim in the commodity market of some European Countries. Accessed: 14 November 2012. http://www.imshealth.com/ims/Global/Content/Home%20Page%20Content/IMS%20News/Biosimilars_Whitepaper.pdf.